BI Asset Management Fondsmaeglerselskab A S Sells 6,413 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

BI Asset Management Fondsmaeglerselskab A S cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 54.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,342 shares of the biopharmaceutical company’s stock after selling 6,413 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Alnylam Pharmaceuticals were worth $1,442,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Korea Investment CORP grew its holdings in shares of Alnylam Pharmaceuticals by 13.0% in the first quarter. Korea Investment CORP now owns 105,759 shares of the biopharmaceutical company’s stock valued at $28,557,000 after acquiring an additional 12,156 shares in the last quarter. Algert Global LLC bought a new position in shares of Alnylam Pharmaceuticals in the first quarter valued at approximately $311,000. American Century Companies Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 9.8% in the first quarter. American Century Companies Inc. now owns 1,760,435 shares of the biopharmaceutical company’s stock valued at $475,353,000 after acquiring an additional 156,411 shares in the last quarter. Aberdeen Group plc grew its holdings in shares of Alnylam Pharmaceuticals by 12.9% in the first quarter. Aberdeen Group plc now owns 215,385 shares of the biopharmaceutical company’s stock valued at $57,054,000 after acquiring an additional 24,544 shares in the last quarter. Finally, Liontrust Investment Partners LLP lifted its stake in Alnylam Pharmaceuticals by 34.6% in the first quarter. Liontrust Investment Partners LLP now owns 18,880 shares of the biopharmaceutical company’s stock valued at $5,098,000 after purchasing an additional 4,857 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Trading Up 2.0%

NASDAQ:ALNY opened at $467.55 on Friday. The company has a market cap of $61.29 billion, a P/E ratio of -189.29 and a beta of 0.25. The stock’s fifty day moving average price is $357.72 and its two-hundred day moving average price is $295.44. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $467.71. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.86. The firm had revenue of $773,689 billion for the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business’s quarterly revenue was up 17.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Buying and Selling

In related news, Director Michael W. Bonney sold 11,250 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $450.00, for a total value of $5,062,500.00. Following the sale, the director owned 16,804 shares in the company, valued at approximately $7,561,800. This trade represents a 40.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 6,979 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $453.27, for a total value of $3,163,371.33. Following the completion of the sale, the chief executive officer owned 56,221 shares in the company, valued at $25,483,292.67. This trade represents a 11.04% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 108,531 shares of company stock valued at $41,087,238 in the last ninety days. 1.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ALNY. BMO Capital Markets upped their price objective on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an “outperform” rating in a research note on Tuesday, June 24th. JPMorgan Chase & Co. upped their price objective on Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an “overweight” rating in a research note on Wednesday, August 6th. Chardan Capital upped their price objective on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Raymond James Financial began coverage on Alnylam Pharmaceuticals in a research note on Wednesday, July 30th. They issued an “outperform” rating and a $370.00 price objective on the stock. Finally, Truist Financial began coverage on Alnylam Pharmaceuticals in a research note on Monday, July 21st. They issued a “buy” rating and a $385.00 price objective on the stock. Twenty-two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $405.33.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.